Bergquist S O, Eriksson I, Eriksson S, Lönnbro N, Runehagen A, Styrud J, Ahlquist G
Department of Infectious Diseases, Kalmar County Hospital, Sweden.
Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):163-6. doi: 10.1016/0732-8893(95)00087-q.
In a Swedish multicenter, comparative, retrospective study, patients with different types of infections--bacteremia-septicemia, genitourinary, intra-abdominal, central nervous system, and lower respiratory tract infections--were randomly selected from the hospital records. Patients treated with cefotaxime twice or three times a day as monotherapy (excluding metronidazole) for at least 1 day (240 cases) were analyzed in terms of clinical and bacteriologic outcome, these results were correlated with the dosing regimen. Similarly high success rates (cure and improvement) at hospital discharge were observed in both group initially treated with cefotaxime 1 g twice daily and 2 g twice daily (97 and 96%, respectively). A total of 73% of patients were initially treated with cefotaxime for only 3 days at most before changing to a lower dose regimen, an alternate intravenous treatment, or oral drug follow-up. Clinical evaluation at hospital discharge revealed a clinical success rate between 87 and 100%, depending on the type of infection.
在一项瑞典多中心、比较性、回顾性研究中，从医院记录中随机选取患有不同类型感染（菌血症 - 败血症、泌尿生殖系统感染、腹腔内感染、中枢神经系统感染和下呼吸道感染）的患者。将每天接受两次或三次头孢噻肟单一疗法（不包括甲硝唑）治疗至少1天的患者（240例）的临床和细菌学结果进行分析，并将这些结果与给药方案相关联。最初接受每日两次1g头孢噻肟和每日两次2g头孢噻肟治疗的两组患者在出院时观察到相似的高成功率（治愈和改善）（分别为97%和96%）。共有73%的患者在改为较低剂量方案、替代静脉治疗或口服药物随访之前，最初仅接受了最多3天的头孢噻肟治疗。出院时的临床评估显示，根据感染类型，临床成功率在87%至100%之间。
